Tatsuaki Takeda

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Topics

Epithelial Mesenchymal Transition

Machine Learning

Metastatic Breast Cancer

Epidermal Growth Factor Receptor

Top Venues

International journal of clinical pharmacy

This page only lists publications with an associated author ORCID identifier.

Publications

Tatsuaki Takeda, Shiho Sugimoto, Jun Matsumoto, Naohiro Iwata, Akihiko Nakamoto, Aya Fukuma Ozaki, Hirofumi Hamano, Noritaka Ariyoshi, Yoshito Zamami
A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. International journal of clinical pharmacy 46 (2) (2024)
Tatsuaki Takeda, Shiho Sugimoto, Jun Matsumoto, Naohiro Iwata, Akihiko Nakamoto, Aya Fukuma Ozaki, Hirofumi Hamano, Noritaka Ariyoshi, Yoshito Zamami
A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. International journal of clinical pharmacy 46 (2) (2024)
Tatsuaki Takeda, Shiho Sugimoto, Jun Matsumoto, Naohiro Iwata, Akihiko Nakamoto, Aya Fukuma Ozaki, Hirofumi Hamano, Noritaka Ariyoshi, Yoshito Zamami
A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. International journal of clinical pharmacy (2024)
Kosuke Ochi, Ken Suzawa, Yin Min Thu, Fumiaki Takatsu, Shimpei Tsudaka, Yidan Zhu, Kentaro Nakata, Tatsuaki Takeda, Kazuhiko Shien, Hiromasa Yamamoto, Mikio Okazaki, Seiichiro Sugimoto, Tadahiko Shien, Yoshiharu Okamoto, Shuta Tomida, Shinichi Toyooka
Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast. Cancer science 113 (10) (2022)
Tatsuaki Takeda, Hiromasa Yamamoto, Ken Suzawa, Shuta Tomida, Shunsaku Miyauchi, Kota Araki, Kentaro Nakata, Akihiro Miura, Kei Namba, Kazuhiko Shien, Junichi Soh, Tadahiko Shien, Yoshihisa Kitamura, Toshiaki Sendo, Shinichi Toyooka
YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers. Cancer science 111 (3) (2020)